Keywords: onyvax, begins, ph, iib, trial, prostate, cancer

Onyvax begins Ph IIb trial of prostate cancer vacc

Article | 27 September 2007

Print This

London, UK-based biotechnology firm Onyvax says that it has begun a new Phase IIb clinical trial of its immunostimulatory agent, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in